PTIE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today, Pain Therapeutics Inc's share price is $0.57. Pain Therapeutics Inc's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2016 was $-0.28. Hence, Pain Therapeutics Inc's Price-to-Free-Cash-Flow Ratio for today is .
During the past 13 years, Pain Therapeutics Inc's highest Price-to-Free-Cash-Flow Ratio was 321.54. The lowest was 0.00. And the median was 33.82.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -100.00% per year.
During the past 13 years, Pain Therapeutics Inc's highest 3-Year average Free Cash Flow per Share Growth Rate was 271.60% per year. The lowest was -100.00% per year. And the median was 3.00% per year.
Pain Therapeutics Inc's Price-to-Free-Cash-Flow ratio for today is calculated as
|Price-to-Free-Cash-Flow Ratio||=||Share Price||/||Free Cash Flow per Share (TTM)|
Pain Therapeutics Inc's Share Price of today is $0.57.
Pain Therapeutics Inc's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2016 was -0.078 (Dec. 2015 ) + -0.069 (Mar. 2016 ) + -0.072 (Jun. 2016 ) + -0.061 (Sep. 2016 ) = $-0.28.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, managements decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Pain Therapeutics Inc Annual Data
Pain Therapeutics Inc Quarterly Data